News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Pfizer Inc. (PFE) Lung Drug Stops Deadly Child Cancers in Study


5/17/2012 7:55:06 AM

A Pfizer (PFE) Inc. drug that has transformed treatment for adult lung cancers caused by a gene defect is now saving children with deadly tumors. Pfizer’s Xalkori eradicated signs of malignancy in some kids with rare tumors of the nerves, blood and soft tissue, according to findings released yesterday in advance of the American Society of Clinical Oncology meeting that starts June 1. The three tumor types can be driven by ALK gene mutations targeted by Xalkori. The results show how medicines that target genetic flaws can be first tested in one cancer and then rapidly applied to other malignancies with the same gene abnormality. The drug helped kids with all three tumors, with the most impressive results seen in a blood cancer called anaplastic large cell lymphoma. In these cases, all signs of cancer vanished in 7 of 8 kids who got the drug.

Read at Bloomberg
Read at MSNBC
Read at Reuters
Read at Fox News

comments powered by Disqus
Bloomberg
MSNBC
Reuters
Fox News
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES